<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364052</url>
  </required_header>
  <id_info>
    <org_study_id>VAL109</org_study_id>
    <nct_id>NCT00364052</nct_id>
  </id_info>
  <brief_title>Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients</brief_title>
  <official_title>Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients: A Single Center Experience With Oral Ganciclovir Versus Valganciclovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <brief_summary>
    <textblock>
      Null Hypothesis:&#xD;
&#xD;
      There is no significant difference in the incidence of CMV infection when using oral&#xD;
      valganciclovir or ganciclovir as prophylactic anti-viral therapy.&#xD;
&#xD;
      Alternate Hypothesis:&#xD;
&#xD;
      There exists a significant difference in the incidence of CMV infection when oral&#xD;
      valganciclovir is used for CMV prophylaxis rather than oral ganciclovir. A formal hypothesis&#xD;
      to be tested should be defined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective for this retrospective clinical study is to describe the incidence of CMV&#xD;
      infection in orthoptic liver transplant recipients who receive oral valganciclovir or&#xD;
      ganciclovir as their CMV prophylactic anti-viral therapy.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary Endpoint&#xD;
&#xD;
      CMV infection will be characterized as viremia, syndrome or disease by the abovementioned&#xD;
      methods for up to one year post-transplantation.&#xD;
&#xD;
      Secondary Endpoints&#xD;
&#xD;
        1. Patient and allograft survival based on donor/recipient CMV status&#xD;
&#xD;
        2. Incidence of graft rejection and loss associated with CMV infection&#xD;
&#xD;
        3. Time to hepatitis C virus (HCV) occurrence&#xD;
&#xD;
        4. Incidence of HSV, EBV and VZV reactivations&#xD;
&#xD;
        5. Severity of HCV occurrence based on biopsy reports based on the Knodell score&#xD;
&#xD;
        6. Safety and tolerability of oral valganciclovir and ganciclovir&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <completion_date>January 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment>200</enrollment>
  <condition>Liver Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral Valganciclovir vs oral Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All liver transplants will be performed at Oregon Health &amp; Science University (OHSU)&#xD;
             and the OHSU surgical and medical staff will treat patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Portland Veterans Affairs Medical Center liver transplant recipients&#xD;
&#xD;
          -  Patients deceased within thirty days of receiving liver allograft&#xD;
&#xD;
          -  Patients with low risk of acquiring CMV infection: donor-negative and&#xD;
             recipient-negative (D-/R-)&#xD;
&#xD;
          -  Patients undergoing re-transplantation&#xD;
&#xD;
          -  Lost to follow-up (minimum follow-up is 1 year)&#xD;
&#xD;
          -  History of CMV infection or disease&#xD;
&#xD;
          -  Anti-CMV therapy within the past 30 d&#xD;
&#xD;
          -  Severe, uncontrolled diarrhea or evidence of malabsorption.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali J Olyaei, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ali J Olyaei, PharmD</last_name>
    <phone>503-494-8132</phone>
    <email>olyaeia@ohsu.edu</email>
  </overall_contact>
  <verification_date>August 2006</verification_date>
  <study_first_submitted>August 11, 2006</study_first_submitted>
  <study_first_submitted_qc>August 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>August 16, 2006</last_update_submitted>
  <last_update_submitted_qc>August 16, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2006</last_update_posted>
  <keyword>Valganciclovir, Oral Ganciclovir, Liver transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

